 |
市場調查報告書
商品編碼
1616250
泌尿生殖藥物市場機會、成長動力、產業趨勢分析與預測 2024 - 2032Genitourinary Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年，全球泌尿生殖藥物市場規模達到 287 億美元，2024 年至 2032 年複合年成長率將達到 2.3%。腫瘤學的最新進展，特別是前列腺癌治療的進展，正在對市場產生重大影響。例如，2024年3月，百時美施貴寶宣布FDA批准Opdivo（nivolumab）合併順鉑和吉西他濱用於第一線治療不可切除或轉移性尿路上皮癌（UC）成年患者。此次批准旨在增強公司的競爭地位和市場影響力。
市場依藥物類型分為荷爾蒙療法、抗感染藥和其他藥物類型。荷爾蒙療法是晚期前列腺癌的主要治療方法，通常利用雄性激素剝奪療法 (ADT) 來降低睪固酮水平。全球前列腺癌發生率的上升增加了對荷爾蒙療法的需求。長效型儲庫製劑無需頻繁給藥，可提高病患依從性和治療效果，進一步推動市場成長。
全球人口老化也增加了對荷爾蒙療法的需求，以治療荷爾蒙相關的泌尿生殖系統疾病，如前列腺癌和良性前列腺增生 (BPH)。在應用方面，到 2023 年，泌尿道感染 (UTI) 領域將佔據超過 31% 的市場佔有率。早期診斷和治療至關重要，這會增加對泌尿道感染藥物的需求並推動市場成長。許多患者會經歷復發性泌尿道感染，需要重複治療。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 287 億美元 |
| 預測值 | 349 億美元 |
| 複合年成長率 | 2.3% |
這種高復發率刺激了對長期預防性治療的需求，從而促進了市場成長。北美泌尿生殖藥物市場預計將以2.1% 的複合年成長率成長，到2032 年將達到154 億美元。的醫療基礎設施和持續的研究和發展。肥胖和糖尿病等與生活方式相關的疾病發病率不斷增加，與泌尿生殖系統疾病的增加有關，進一步推動了市場的成長。美國食品藥物管理局 (FDA) 的監管批准在塑造市場格局方面發揮著至關重要的作用，新藥的批准擴大了治療選擇。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 泌尿生殖系統疾病盛行率增加
- 藥物開發技術的進步
- 藥物傳輸技術的進步
- 產業陷阱與挑戰
- 來自非藥物療法的競爭
- 與泌尿生殖藥物相關的顯著副作用
- 成長動力
- 成長潛力分析
- 監管環境
- 未來市場趨勢
- 管道分析
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀錶板
第 5 章：市場估計與預測：按藥物類型，2021 - 2032
- 主要趨勢
- 荷爾蒙療法
- 雄激素
- 雌激素
- 其他荷爾蒙療法
- 抗感染
- 抗生素
- 抗黴菌藥
- 抗病毒藥
- 其他藥物類型
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 泌尿道感染（UTI）
- 良性攝護腺增生（BPH）
- 攝護腺癌
- 膀胱過動症
- 膀胱癌
- 其他應用
第 7 章：市場估計與預測：按給藥途徑，2021 - 2032 年
- 主要趨勢
- 口服
- 注射用
- 專題
第 8 章：市場估計與預測：按配銷通路，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 藥局和零售藥局
- 網路藥局
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Abbott Laboratories
- Allergan, Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd
The Global Genitourinary Drugs market size reached USD 28.7 billion in 2023 and will record 2.3% CAGR between 2024 and 2032. Innovative hormonal therapies are driving industry growth by offering more effective and safer options. Recent advancements in oncology, particularly in prostate cancer therapeutics, are significantly impacting the market. For instance, in March 2024, Bristol Myers Squibb announced FDA approval for Opdivo (nivolumab) combined with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). This approval is set to enhance the company's competitive position and market reach.
The market is segmented by drug type into hormonal therapy, anti-infectives, and other drug types. Hormonal therapy serves as a primary treatment for advanced prostate cancer, often utilizing androgen deprivation therapy (ADT) to lower testosterone levels. The global rise in prostate cancer incidence is increasing the demand for hormonal therapies. Long-acting depot formulations, which require less frequent dosing, improve patient compliance and treatment outcomes, further driving market growth.
The aging global population is also raising the demand for hormonal therapies to manage hormone-related genitourinary disorders such as prostate cancer and benign prostatic hyperplasia (BPH). In terms of applications, the urinary tract infections (UTIs) segment held over 31% market share in 2023. Public health campaigns have increased awareness of UTI symptoms and complications, leading to higher diagnosis rates. Early diagnosis and treatment are crucial, boosting the demand for UTI medications and driving market growth. Many patients experience recurrent UTIs, necessitating repeated treatments.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $28.7 Billion |
| Forecast Value | $34.9 Billion |
| CAGR | 2.3% |
This high recurrence rate fuels the demand for long-term and prophylactic therapies, contributing to market growth. North America genitourinary drugs market is projected to grow at a CAGR of 2.1%, reaching USD 15.4 billion by 2032. The U.S. market, a significant segment of the pharmaceutical industry, is driven by a high prevalence of genitourinary disorders, advanced healthcare infrastructure, and ongoing research and development. The increasing incidence of lifestyle-related disorders such as obesity and diabetes is linked to a rise in genitourinary conditions, further fueling market growth. Regulatory approvals by the U.S. Food and Drug Administration (FDA) play a crucial role in shaping the market landscape, with new drug approvals expanding treatment options.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of genitourinary disorders
- 3.2.1.2 Rise in advancement in drug development technology
- 3.2.1.3 Technological advancement in drug delivery
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Competition from non-pharmaceutical therapies
- 3.2.2.2 Significant side effects associated with genitourinary drugs
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Future market trends
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Hormonal therapy
- 5.2.1 Androgen
- 5.2.2 Estrogen
- 5.2.3 Other hormonal therapy
- 5.3 Anti-infective
- 5.3.1 Antibiotics
- 5.3.2 Antifungals
- 5.3.3 Antivirals
- 5.4 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Urinary tract infections (UTIs)
- 6.3 Benign prostatic hyperplasia (BPH)
- 6.4 Prostate cancer
- 6.5 Overactive bladder
- 6.6 Bladder cancer
- 6.7 Other applications
Chapter 7 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Parenteral
- 7.4 Topical
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Drug store & retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Allergan, Inc.
- 10.3 AstraZeneca Plc
- 10.4 Bayer AG
- 10.5 Bristol-Myers Squibb Co.
- 10.6 Eli Lilly and Company
- 10.7 F. Hoffmann-La Roche Ltd.
- 10.8 GlaxoSmithKline Plc
- 10.9 Ionis Pharmaceuticals, Inc.
- 10.10 Merck & Co., Inc.
- 10.11 Novartis AG
- 10.12 Pfizer, Inc.
- 10.13 Teva Pharmaceutical Industries Ltd
